Navigation Links
Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
Date:9/13/2011

EAST BRUNSWICK, N.J., Sept. 13, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that John H. Johnson, Chief Executive Officer and President of Savient will present at the Sixth Annual JMP Securities Healthcare Conference on Wednesday, September 28, 2011 at 9:30 a.m. Eastern Time.  The conference will be held at the St. Regis hotel in New York City.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy.  Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA.  MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.  For more information, please visit the Company's website at www.savient.com.

SVNT - GContact:Mary Coleman

Carney Noensie Savient Pharmaceuticals, Inc.

Burns McClellaninformation@savient.com

cnoensie@burnsmc.com (732) 418-9300

(212) 213-0006
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
2. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
3. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
4. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
5. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
6. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
7. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
8. Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
9. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
10. Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress
11. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Januar 2017  ResMed (NYSE: RMD ), ... Medical ( Winter Haven, Florida ) gaben ... die Beilegung aller globalen Rechtsstreitigkeiten zwischen den Parteien geeinigt ... ihrer bestehenden Produkte im Tausch gegen Lizenzgebühren an ResMed ... leisten, um das in Florida ...
(Date:1/23/2017)... Just two weeks remain until legal experts and senior industry ... Central London to discuss the flow of pharmaceutical products ... Parallel Trade 2017 . In the run up to ... is available to read in the event download centre . ... Some of those confirmed include: ...
(Date:1/21/2017)... PUNE, India , January 20, 2017 ... by Type (Descriptive, Prescriptive), Application (Marketing, R&D, Compliance, SCM), Component (Software, ... CRO) - Forecasts to 2021" published by MarketsandMarkets, the market is ... Billion in 2016, at a CAGR of 13.3% during the forecast ... ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... ... in partnership with the American Society of Anesthesiologists® (ASA®), the Foundation for ... American Academy of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages proposals ...
(Date:1/23/2017)... ... January 23, 2017 , ... The ... at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities and individuals about ... been developed for use by nutrition educators and influencers within the public ...
(Date:1/22/2017)... ... 22, 2017 , ... Phytocéane invites clients to take an exotic journey deep ... with ZANZIBAR MILKY CREAM. Inspired by the beauty of Zanzibar, a Tanzanian archipelago off ... moisturizing vegetal coral to create this gentle, velvety body cream to envelop the skin ...
(Date:1/21/2017)... , ... January 21, 2017 , ... Caronlab Australia, an ... the January ECRM Trade Show in Hilton Head, SC, where it benefited from outstanding ... the quality of its beauty and wellness products. At this trade show, the company ...
(Date:1/21/2017)... ... 21, 2017 , ... Phytocéane invites you to take an exotic ... the world with ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, a Tanzanian ... and moisturizing vegetal coral to create this gentle, crystal-clear shower gel to cleanse the ...
Breaking Medicine News(10 mins):